<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263663</url>
  </required_header>
  <id_info>
    <org_study_id>RESIST</org_study_id>
    <nct_id>NCT03263663</nct_id>
  </id_info>
  <brief_title>Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model</brief_title>
  <acronym>2016-003295-46</acronym>
  <official_title>Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Volker Heinemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MGO Ruhr-University Bochum (RUB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this exploratory phase II trial, the possibility of a personalized treatment after&#xD;
      resistance to cetuximab will be evaluated. Therefore, tumor material of all patients shall be&#xD;
      obtained, transferred into avatars and treated the same way as in the patient until&#xD;
      resistance arises. These resistant tumor cells are subsequently treated by different targeted&#xD;
      treatment combinations in the mouse avatar model to find the most active drug or combination&#xD;
      of drugs. This drug or combination of drugs may then be offered to the patient after&#xD;
      cetuximab resistance has occurred. Multiple liquid biopsies shall be obtained in patients&#xD;
      during first-line treatment with cetuximab as well as during second line experimental&#xD;
      treatment to monitor mutations that may be associated with cetuximab resistance. Furthermore&#xD;
      at the time of resistance a biopsy should be taken and analyzed to ensure that the mechanism&#xD;
      of resistance seen in the avatar model matches with the mechanism of resistance in the&#xD;
      individual patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>5-7 months</time_frame>
    <description>according to RECIST 1.1</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>RAS Wild-type</condition>
  <condition>UICC III</condition>
  <condition>UICC II + RF</condition>
  <condition>UICC IV Curative Intent</condition>
  <arm_group>
    <arm_group_label>Chemotherapy plus targeted treatment</arm_group_label>
    <description>Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy according to physician choice standard</arm_group_label>
    <description>Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>targeted substance according to the avatar model</intervention_name>
    <description>individualized second line treatment</description>
    <arm_group_label>Chemotherapy plus targeted treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Primary tumormaterial&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        locally advanced colorectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients age â‰¥ 18 years&#xD;
&#xD;
          -  Written declaration of consent&#xD;
&#xD;
          -  ECOG Performance Status 0-1&#xD;
&#xD;
          -  Life expectancy&gt; 3 months&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum at stage UICC III or&#xD;
             UICC IV&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum in stage UICC II with&#xD;
             one of the following risk factors: CEA&gt; 200; T4 tumor, emergency surgery, &lt;12 distant&#xD;
             lymph nodes, surgery due to intestinal obstruction (ileus)&#xD;
&#xD;
          -  Patient agrees to the preservation of tumor material for the purpose of molecular&#xD;
             analyzes including the determination of the genetic profile of the tumor&#xD;
             (participation in the project &quot;RESIST&quot;)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative Radiotherapy&#xD;
&#xD;
          -  Preoperative chemotherapy&#xD;
&#xD;
          -  Heart failure&gt; Grade II (functional NYHA classification)&#xD;
&#xD;
          -  Existing concomitant disease or condition that would make the patient unsuitable for a&#xD;
             study participation or interfere with the safety of the subject&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical event which does not allow&#xD;
             observance of the study protocol&#xD;
&#xD;
          -  Additional carcinoma therapy (chemotherapy, radiation, biological therapy,&#xD;
             immunotherapy or hormonal therapy) during the study&#xD;
&#xD;
          -  Known malignant second neoplasia within the last 5 years (except for a basal cell&#xD;
             carcinoma or a carcinoma in situ of the uterine cervix).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
    <phone>+49 89 4400 0</phone>
    <email>sebastian.stintzing@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Munich - Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
      <phone>+49 89 4400 0</phone>
      <email>sebastian.stintzing@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Director of the CCC LMU</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

